Zomedica Q2 revenue $9.5M (+37% YoY), net loss down 49% to $3.8M

Zomedica Corp.

2026-Q2 EPS reported -$0.01 revenue$18,311,000

Record Q2 revenue of $9.5M, up 37% YoY; net loss reduced 49% to $3.8M from $7.4M.
Diagnostics segment revenue grew 77% to $1.4M; Therapeutic Devices up 9% to $6.8M.
Cash burn improved 38% to $3.4M; operating expenses down 20% to $10.1M.
Cash and securities $44.1M; 22nd consecutive quarter of YoY revenue growth.
Development Services segment contributed $1.4M in Q2, $3.4M YTD.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.